Living medicines engineered from patient or donor cells to fight disease. CAR-T cells have transformed blood cancer treatment; next-generation approaches include allogeneic (off-the-shelf), CAR-NK, and tumor-infiltrating lymphocyte (TIL) therapies.
From a single lupus patient in Erlangen to pediatric trials in Rome, allogeneic programs at Allogene, and dual-targeted CD19/CD70 designs — CAR-T cell therapy is rewriting autoimmune medicine. We map the landscape: which diseases, which constructs, and who's winning the race to scale.
Apr 16, 2026 · 14 min read
In a novel approach, the FDA approves re-dosing a CAR-T cell therapy in ovarian cancer after initial tumor inflammation showed signs of immune engagement. A potential paradigm shift for solid tumor cell therapy.
Apr 16, 2026 · 5 min read
The first lupus patient treated with CD19 CAR-T cells in 2021 at University Hospital Erlangen remains in complete remission. Across expanding trials, most of dozens of patients have sustained drug-free responses, validating a paradigm shift from chronic immunosuppression to one-time cellular reset.
Apr 9, 2026 · 7 min read
The first CRISPR-based therapy, Casgevy for sickle cell disease and beta-thalassemia, is now approved in the US, EU, UK, Canada, and six additional countries. Real-world data confirms durable transfusion independence.
Apr 2, 2026 · 6 min read
An innovative CAR-T therapy targeting T-cell cancers — historically difficult because CAR-T cells attack each other — receives Breakthrough Therapy designation, opening a new frontier in cell therapy.
Mar 25, 2026 · 5 min read
Foundation model for single-cell multi-omics built on generative pre-training of ~33M cells. Fine-tunes to SOTA on cell type annotation, multi-batch integration, perturbation prediction, and gene network inference.
Automated cell type annotation tool for scRNA-seq data using logistic regression models trained on curated cross-tissue immune cell atlases. Provides a growing encyclopedia of pre-trained cell type models.
Transformer-based foundation model pre-trained on ~30M single-cell transcriptomes. Learns context-dependent gene network dynamics and transfers to diverse downstream tasks including disease modeling and therapeutic target prioritization.